CDTX - Cidara Therapeutics Inc Stock Price, Fair Value and News

$23.22+0.71 (+3.15%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CDTX Price Action

Last 7 days

1.5%

Last 30 days

53.6%

Last 90 days

106.0%

Trailing 12 Months

57.3%

CDTX RSI Chart

CDTX Valuation

Market Cap

163.6M

Price/Earnings (Trailing)

-1.36

Price/Sales (Trailing)

3.18

EV/EBITDA

-0.3

Price/Free Cashflow

-1.02

CDTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CDTX Fundamentals

CDTX Revenue

Revenue (TTM)

51.4M

Rev. Growth (Yr)

-94.07%

Rev. Growth (Qtr)

-96.43%

CDTX Earnings

Earnings (TTM)

-120.7M

Earnings Growth (Yr)

-75.52%

Earnings Growth (Qtr)

82.47%

CDTX Profitability

EBT Margin

-231.83%

Return on Equity

-104.41%

Return on Assets

-74.37%

Free Cashflow Yield

-97.88%

CDTX Investor Care

Shares Dilution (1Y)

55.84%

Diluted EPS (TTM)

-25.42

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	56.2M	51.4M	0	0
2023	83.3M	82.2M	50.6M	73.8M
2022	54.4M	27.8M	61.5M	64.4M
2021	11.9M	41.4M	46.1M	49.6M
2020	23.9M	26.8M	10.2M	12.1M
2019	0	0	0	20.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CEO	Dr. Jeffrey L. Stein Ph.D.
WEBSITE	cidara.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	73

Cidara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cidara Therapeutics Inc? What does CDTX stand for in stocks?

CDTX is the stock ticker symbol of Cidara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cidara Therapeutics Inc (CDTX)?

As of Fri Dec 20 2024, market cap of Cidara Therapeutics Inc is 163.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDTX stock?

You can check CDTX's fair value in chart for subscribers.

Is Cidara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CDTX is over valued or under valued. Whether Cidara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cidara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDTX.

What is Cidara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CDTX's PE ratio (Price to Earnings) is -1.36 and Price to Sales (PS) ratio is 3.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDTX PE ratio will change depending on the future growth rate expectations of investors.